features make collaboration smoother than ever .
What ' s even more impressive is that AugmentoTM is vendor-neutral , capable of seamlessly integrating AI models developed by DeepTek . ai or other sources directly into existing workflows . This adaptability means healthcare providers can tailor their AI use to match their unique needs , without disrupting their established processes . AugmentoTM has also been adopted by the esteemed Singapore Healthtech Agency , now known as Synapxe . AugmentoTM is a crucial component of AIIM . SG , a groundbreaking platform aimed at accelerating the adoption of AIpowered medical imaging diagnostics .
Which clients and regions do you cater to in Asia and globally ? Have your efforts to expand brand visibility and generate interest from key markets evoked any interest from investors so far ?
Deeptek ' s reach spans continents , serving as a pivotal player in the healthcare sectors across Asia-Pacific . Leading hospitals and imaging centers in Japan , Singapore , Thailand , the Philippines , Nigeria , and Kenya have all benefited from Deeptek ' s solutions .
“ We envision to emerge as the foremost global hub for X-ray reporting outsourcing .”
A strategic partnership with Synapxe , has propelled AugmentoTM into the heart of Singapore ' s health system . Having obtained US FDA clearance for AugmentoTM , we now have our sights set on expansion across the US and Europe . We are set to introduce AugmentoTM X Ray , an innovative Chest X-Ray Reporting Automation Tool tailored for these regions .
Investor interest has been a harmonious note in Deeptek ' s journey . A USD 10 million injection from a Series A round led by Tata Capital Healthcare Fund , along with contributions from Pentathlon Ventures and GHV Accelerator , marked a significant milestone in 2022 . Prior to this , NTT DATA ' s seed funding had already set the tone for Deeptek ' s trajectory .
Key partnerships with industry players like Shimadzu Asia Pacific , BJC Healthcare , and Shimadzu Middle East have further amplified our global footprint .
How has the company performed financially so far and your revenue outlook for next few years ?
Presently , the majority of our revenue originates from markets beyond India , with approximately two-thirds stemming from the Asia Pacific region . Looking ahead to the next two to three years , our target is to achieve revenues surpassing US $ 15 million .
HealthTech
BIOVOICENEWS . COM 47